Atsena secures DMC approval for LIGHTHOUSE trial
Screening is planned to begin in April 2026, with enrolment completion expected by the end of the first quarter of 2027.
Analysis
View MoreAPIs to the rescue?
Oral bioavailability remains one of the biggest challenges in drug development, particularly for small-molecule APIs with poor solubility or permeability. Liam Critchley explores how pharmaceutical companies are using integrated formulation...
AI now: What QbD and PAT missed
Cool heads, smart chains
Sustainability vs suitability
Integrating sustainability compliance